India, May 16 -- BioMarin Pharmaceutical Inc. (BMRN) and Inozyme Pharma, Inc. (INZY) Friday said that BioMarin has agreed to acquire Inozyme for about $270 million or $4 per share, in cash.
The deal is expected to close in the third quarter of 2025.
The acquisition will add a Phase 3 enzyme replacement therapy, INZ-701 to BioMarin's portfolio. INZ-701 is currently being evaluated for the treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) Deficiency, a rare, serious and progressive genetic condition that affects blood vessels, soft tissues and bones. Data from the first Phase 3 pivotal study of INZ-701 in children is expected in early 2026.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'...